<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00980213</url>
  </required_header>
  <id_info>
    <org_study_id>R09045</org_study_id>
    <nct_id>NCT00980213</nct_id>
  </id_info>
  <brief_title>Evaluation of the Cost and Effectiveness Sunitinib Compared to Interferon-Alfa in Finland</brief_title>
  <official_title>Evaluation of the Cost and Effectiveness in the First-line Treatment of Advanced Renal Cell Cancer With Sunitinib Compared to Interferon-alfa in Finland.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pirkko-Liisa Kellokumpu-Lehtinen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Turku</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Oulu University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Tampere University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patient receiving sunitinib according the clinician's independent decision as first-line&#xD;
      treatment of advanced renal cell carcinoma (RCC) will be asked for informed consent.&#xD;
      Treatment with sunitinib will start and end solely on the treating clinicians and the&#xD;
      patients independent discretion. Consenting patients will prospectively answer standardized&#xD;
      quality of life questionnaires (15D, EQ-5D) during the treatment. Data on health care&#xD;
      resource utilisation will be collected prospectively (outpatient visits, hospital stays,&#xD;
      concomitant drugs, investigations, sick-leaves, travels). In addition, after treatment&#xD;
      failure anti-cancer drugs, hospital stays and date of death will be recorded.&#xD;
&#xD;
      The health economic data during sunitinib treatment and the length of the sunitinib treatment&#xD;
      will be compared with the corresponding previously published data collected retrospectively&#xD;
      from patients with the same condition treated with IFN-alfa. Stepwise regression analysis&#xD;
      will be used to explore whether patient and tumor characteristics explain potential variation&#xD;
      in treatment duration and costs that is not explained by the treatment.&#xD;
&#xD;
      Health-related quality of life (HRQoL) data will be presented as descriptive data and&#xD;
      compared to age-standardized general population.&#xD;
&#xD;
      At least four major Finnish oncology centers have consented to participate in this study. The&#xD;
      inclusion time will be approximately 24 months, and the study time approximately 48 months.&#xD;
      Eighty patients will be included.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incremental cost per incremental time to treatment failure (TTF) in first-line treatment</measure>
    <time_frame>1 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Health related quality of life (HRQoL)</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">80</enrollment>
  <condition>Neoplasms</condition>
  <condition>Renal Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>sunitinib</arm_group_label>
    <description>advanced renal cell cancer patients treated with sunitinib as first-line therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sunitinib</intervention_name>
    <description>sunitinib 50 mg, per os, daily for 4 weeks then 2 weeks pause, duration months</description>
    <arm_group_label>sunitinib</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        advanced renal cell cancer patients&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Clinically indicated first-line sunitinib treatment for advanced RCC.&#xD;
&#xD;
          -  Informed consent obtained.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unable to complete HRQoL forms.&#xD;
&#xD;
          -  Not consenting to collecting register data.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Kuopio University Hospital</name>
      <address>
        <city>Kuopio</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oulu Univeristy Hospital</name>
      <address>
        <city>Oulu</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tampere University Hospital</name>
      <address>
        <city>Tampere</city>
        <zip>Fi-33521</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Turku University Hospital</name>
      <address>
        <city>Turku</city>
        <zip>Fi-20520</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vaasa Central Hosptital</name>
      <address>
        <city>Vaasa</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <study_first_submitted>September 18, 2009</study_first_submitted>
  <study_first_submitted_qc>September 18, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2009</study_first_posted>
  <last_update_submitted>February 5, 2014</last_update_submitted>
  <last_update_submitted_qc>February 5, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 6, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Tampere University Hospital</investigator_affiliation>
    <investigator_full_name>Pirkko-Liisa Kellokumpu-Lehtinen</investigator_full_name>
    <investigator_title>Prof</investigator_title>
  </responsible_party>
  <keyword>renal cell cancer</keyword>
  <keyword>sunitinib</keyword>
  <keyword>costs</keyword>
  <keyword>quality of life</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sunitinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

